Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis

Molecular Cancer Research

Volumn 14, Issue 10, 2016, Pages 976-983

  Johannessen, Tor Christian Aase ^a,b   Mukherjee, Joydeep ^a   Viswanath, Pavithra ^a   Ohba, Shigeo ^a   Ronen, Sabrina M ^a   Bjerkvig, Rolf ^b   Pieper, Russell O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; ISOCITRATE DEHYDROGENASE 1; AGI-5198; ALPHA-HYDROXYGLUTARATE; BENZENEACETAMIDE DERIVATIVE; GLUTARIC ACID DERIVATIVE; HISTONE; IDH1 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; ISOCITRATE DEHYDROGENASE;

ARTICLE; ASTROCYTE; CARCINOGENESIS; CELL PROLIFERATION; CELL TRANSFORMATION; CLONOGENESIS; CONTROLLED STUDY; EXPOSURE; GLIOMA; GLIOMA CELL; HISTONE METHYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; BRAIN TUMOR; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; METHYLATION; MUTATION; TUMOR CELL LINE;

ASTROCYTES; BENZENEACETAMIDES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; GLIOMA; GLUTARATES; HISTONES; HUMANS; IMIDAZOLES; ISOCITRATE DEHYDROGENASE; METHYLATION; MUTATION;

EID: 84991660847     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0141     Document Type: Article

References (40)

1. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cyto-genetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28: 3636-43.
2. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan, Chen K, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Eng J Med 2009;361:1058-61.
3. Shibata T, Kokubu A, Miyamoto M, Sasajima Y, Yamazaki N. Mutant IDH1 confers an in vivo growth advantage in a melanoma cell line with BRAF mutation. Am J Path 2011;178:1395-402.
4. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
5. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Eng J Med 2009;360:765-73.
6. Balss J, Meyer J, Mueller W, Korchunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuro-pathol 2008;116:597-602.
7. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-47.
8. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 2013;73;496-501.
9. Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer JG, et al. A tale of two subunits: how the neomorphic R132H mutation enhances production of aHG. Biochemistry 2011;50:4804-12.
10. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 2011;19:17-30
11. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phe-notype, disrupt TET2 function, and impair hematopoetic differentiation. Cancer Cell 2010;18:553-67.
12. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, et al. IDH1 (R132H) mutation increase murine haematopoietic progenitors and alters epigenetics. Nature 2012;488:656-9.
13. Koch CM, Andrews RM, Flicek P, Dillon SC, Karoaz U, Clelland GK, et al. The landscapeof histone modifications across1%ofthe human genome in five human cell lines. Genome Res 2007;176:691-707.
14. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007;1294:823-37.
15. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-8.
16. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626-30.
17. Chaumiel MM, Larson PEZ, Yoshihara HAI, Danforth OM, Vigneron DB, Nelson SJ, et al. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nature Comm 2013;4:2429-41.
18. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 2011;29:4482-90
19. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early eventsin the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009;174:1149-53
20. Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 2014;343:189-93.
21. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012;3:1194-203.
22. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 2016;27:599-608.
23. Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydro-genase mutations in cancer. Clin Cancer Res 2016;22:1837-42.
24. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013;339:1621-5.
25. Kernytsky A, Wang F, Hansen E, Schalm S, Straley K, Gliser C, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 2015;125:296-303.
26. Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schapp FG, et al. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget 2015;6:12505-19.
27. Ma S, Jiang B, Deng W, Gu Z-K, Wu F-Z, Li T, et al. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth. Oncotarget 2015;6:8606-20.
28. Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell 2015;28:773-84.
29. Ohba S, Mukherjee J, See WL, Pieper RO. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res 2014;74:4836-44.
30. Ohba S, Mukherjee J, Johannessen T-C, Mancini A, Chow TT, Wood M, et al. Mutant IDH1 expression drives TERT promoter reactivation as part of the cellular transformation process. Neuro Oncol 2015;17(Suppl 5): v55.
31. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Chan T. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479-83.
32. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, et al. Formation of intracranial tumors by genetically modified human astro-cytes defines four pathways critical in the development of human ana-plastic astrocytoma. Cancer Res 2001;61:4956-60.
33. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break-and mismatch repair-independent DNA damage. PLoS One 2013;8: e62351.
34. Sonoda Y, Ozawa T, Aldape KD, Berger MS, Deen DF, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 2001;61: 6674-78.
35. Izquierdo-Garcia JL, Cai LM, Chaumeil MM, Eriksson P, Robinson AE, Pieper RO, et al. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One 2015;10:e0118781.
36. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 2001;7:235-9.
37. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45.
38. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 2002;297:102-4.
39. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400:468-72.
40. Jin G, Pirozzi CJ, Chen LH, Lopez GY, Duncan CG, Feng J, et al. Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget 2012;3:774-82.